Press release

TrippBio in the news

TrippBio receives Notice of Allowance from the U.S. Patent Office for Therapeutic Treatment of COVID-19 Infections

Click here to read full press release.

TrippBio announces publication of data supporting the antiviral potency of TD-213 against SARS-CoV-2

Click here to read full press release.

TrippBio, Inc. announces David E. Martin, PharmD as new President and Chief Executive Officer

Click here to read full press release.

TRIPPBIO launched Annual report  

Click here to read annual report 2020.


We are proud to announce that Ralph Tripp, PhD, University of Georgia professor and TrippBio’s Chief Science Officer has been invited by the FDA to join the Advisory Committee of independent medical experts who will review and then vote to recommend the Emergency Use Authorization of the first COVID-19 vaccine in the USA.

“I’m honored to be part of this process and look forward to reviewing the data with my peers,” said Dr. Tripp.

The committee meets today, December 10, and the FDA is expected to provide its decision soon after. 

“The fact that Ralph was invited to join this prestigious group of medical advisors is testimony to his standing and profound expertise in infectious diseases,” stated TrippBio CEO & President, Philip Young. “At TrippBio, we are hopeful that our continued work in the space of COVID-19 therapeutics, coupled with the authorization and distribution of vaccinations in 2021, will help enable the world to better manage this pandemic and improve patient outcomes around the globe.”


Thanks to equity crowdfunding platforms like Netcapital, everyday people have an opportunity to become private investors. Previously, various regulations prevented access to private equity. But with advancing technologies and changing laws, today’s retail market participants have unprecedented access to formerly exclusive sectors. more


JACKSONVILLE, Fla. and BOCA RATON, Fla., Nov. 16, 2020 /PRNewswire/ — TrippBio is dedicated to developing groundbreaking treatments for viral infections, initially targeting COVID-19. TrippBio is developing a patent-pending repurposed FDA-approved drug called TD213. TD213 is administered orally twice daily and works by blocking replication of the SARS-CoV-2 virus and the associated acute inflammatory response to the infection. TrippBio is founded on the scientific research of Ralph Tripp, Ph.D., Georgia Research Alliance Chair and professor at the University of Georgia.    more


Dr. Moti N. Ramgopal of Midway Immunology and Research Center launched the investigator-initiated study (IIS) to assess the efficacy of TD213 in treating patients with confirmed mild – moderate COVD-19 infections. Dr. Ramgopal announced the final patient was enrolled in this proof of concept (POC) study and all participants are progressing through the protocol designated testing and follow-up visits. Recognized as one of the leading infectious disease doctors in the United States, Dr. Ramgopal’s research center is committed to all the health needs of the patient.  more


JACKSONVILLE, Fla., Sept. 23, 2020 /PRNewswire/ — TrippBio is a new biotechnology company launching a crowdfunding investment opportunity to develop a groundbreaking treatment for COVID-19. TrippBio has a repurposed Food and Drug Administration (FDA) drug (TD213) that demonstrated high efficacy in eliminating COVID-19 in preliminary testing. Public support is needed to commence clinical trials and prepare for commercialization. more


Sign up for insider tips and health care news

No paperwork, no hassle. We keep things digital and easy.